<DOC>
	<DOCNO>NCT00701298</DOCNO>
	<brief_summary>This phase I trial study side effect decitabine give together without interferon alfa-2b , best dose interferon alfa-2b , treat patient unresectable metastatic solid tumor . Drugs use chemotherapy , decitabine , work different way stop growth tumor cell , either kill cell stop dividing . Biological therapy , interferon alfa-2b , may stimulate immune system different way stop tumor cell grow . It yet know whether decitabine effective give without interferon alfa-2b treating solid tumor .</brief_summary>
	<brief_title>Decitabine With Without Interferon Alfa-2b Treating Patients With Unresectable Metastatic Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess toxicity decitabine plus escalating dos pegylated interferon alfa-2b ( PEG-Intron ) patient metastatic solid tumor . II . To identify dose-limiting toxicity decitabine combination escalate dos pegylated interferon alfa-2b patient . III . To identify maximum tolerate dose pegylated interferon alfa-2b combination decitabine patient . SECONDARY OBJECTIVES : I . To evaluate pretreatment post-treatment blood tumor sample identify change global ( genomic ) DNA methylation . II . To evaluate pretreatment post-treatment blood , skin tumor sample identify change Mage-1 mRNA protein expression , DNMT-1 level ( due sequestration 5-azacytidine ) , p53 induction ( evidence DNA damage response ) , well change level 2 ' 5'-oligoadenylate synthesis , MxA HLA class I indicators interferon response . III . To evaluate complete partial response rate patient receive decitabine combination escalate dos pegylated interferon alfa-2b . OUTLINE : This dose-escalation study pegylated interferon alfa-2b . Patients assign 1 2 treatment group . GROUP 1 ( control ) : Patients receive decitabine IV 1 hour day 1-5 8-12 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients experience disease progression first course treatment may crossover receive treatment group 2 . GROUP 2 : Patients receive decitabine group 1 pegylated interferon alfa-2b subcutaneously day 1 , 8 , 15 , 22 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients undergo blood sample , normal skin , tissue biopsy collection baseline periodically study . Blood , normal skin , tissue sample analyze global ( genomic ) DNA methylation ( gene-promoter methylation , gene protein expression , p53 induction DNA damage ) interferon level high-performance ( pressure ) liquid chromatography PCR methylation assay , pharmacodynamic study . After completion study treatment , patient follow 28 day every 3 month .</detailed_description>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Biopsyproven solid tumor Metastatic unresectable disease Tumor amenable biopsy No curative effective treatment disease exist , opinion investigator Measurable disease scan assess RECIST criterion No untreated brain metastasis No longer receive steroid therapy previously treat brain metastasis Zubrod performance status 02 Bilirubin ≤ 1.5 time upper limit normal ( ULN ) SGOT SGPT ≤ 2.5 time ULN ( ≤ 5 ULN hepatic metastasis present ) Serum creatinine ≤ 1.5 time ULN Creatinine clearance ≥ 50 mL/min ANC &gt; 1,500/μL Platelet count &gt; 100,000/μL Hemoglobin &gt; 9 g/dL ( transfusion allow ) No NYHA class IIIIV cardiac problem ( e.g. , congestive heart failure myocardial infarction within past 2 month ) No severe and/or uncontrolled concurrent medical disease ( e.g. , uncontrolled diabetes , uncontrolled chronic renal liver disease , active uncontrolled infection [ e.g. , HIV ] ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception 3 month completion study therapy Willing undergo biopsies No medical psychological condition , opinion investigator , may preclude patient 's ability tolerate complete treatment , grant reliable inform consent No prior malignancy except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , adequately treated stage I , II , III cancer patient currently complete remission , cancer patient diseasefree 5 year No prior extensive pelvic irradiation prolong nucleoside analogue pretreatment At least 28 day since prior concurrent chemotherapy , radiotherapy , surgery , biological therapy , anticancer agent , investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>